Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia

Tyler A Berger,1 Matthew W Manry,1,2 Lucas B Lindsell,1,2 James M Osher,1,2 Daniel M Miller,1,2 Robert E Foster,1,2 Christopher D Riemann,1,2 Michael R Petersen,1,2 Robert A Sisk1– 3 1Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA; 2Cincinnati Eye Institute, Cin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Berger TA, Manry MW, Lindsell LB, Osher JM, Miller DM, Foster RE, Riemann CD, Petersen MR, Sisk RA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	antioxidant areds2 carotenoid supplementation ellipsoid zone loss lutein idiopathic macular telangiectasia macular telangiectasia juxtafoveal macular telangiectasia parafoveal telangiectasia retinal vascular disease. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/b54a859aabc144b6b64c320b371c802d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b54a859aabc144b6b64c320b371c802d
record_format	dspace
spelling	oai:doaj.org-article:b54a859aabc144b6b64c320b371c802d2021-12-02T13:34:19ZOutcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia1177-5483https://doaj.org/article/b54a859aabc144b6b64c320b371c802d2021-03-01T00:00:00Zhttps://www.dovepress.com/outcome-of-off-label-areds-2-supplementation-for-the-treatment-of-macu-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Tyler A Berger,1 Matthew W Manry,1,2 Lucas B Lindsell,1,2 James M Osher,1,2 Daniel M Miller,1,2 Robert E Foster,1,2 Christopher D Riemann,1,2 Michael R Petersen,1,2 Robert A Sisk1– 3 1Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA; 2Cincinnati Eye Institute, Cincinnati, OH, USA; 3Abrahamson Pediatric Eye Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USACorrespondence: Robert A SiskCincinnati Eye Institute, 1945 CEI Drive, Cincinnati, OH, 45242, USAFax +1 513-569-3904Email rsisk@cvphealth.comPurpose: To evaluate if off-label Age-Related Eye Disease Study 2 (AREDS2) supplementation prevents visual and anatomical deterioration in non-proliferative Idiopathic Macular Telangiectasia Type 2 (IMT2).Patients and Methods: This is a single-center retrospective, comparative study of 82 IMT2 eyes treated with AREDS2 from January 1st, 2013 to January 1st, 2018. The study analysis consisted of a non-comparative arm, which included all AREDS2 eyes, and a comparative arm (27 AREDS2 and 42 untreated eyes) that only included eyes with complete follow-up data. Eyes were evaluated at baseline, 12 and 24 months. Better/worse eye sub-analysis was performed in the comparative study arm. Primary outcomes were best corrected visual acuity (BCVA) and optical coherence tomography (OCT) anatomical characteristics including largest cavitation diameter, central macular thickness (CMT), and length of ellipsoid zone (EZ) loss at 24 months.Results: In the non-comparative arm, AREDS2 eyes showed stable BCVA (0.28 ± 0.18 logMAR at baseline vs 0.26 ± 0.19 logMAR at 24 months; p = 0.35) and OCT anatomical features after 24 months of supplementation. In the comparative arm, BCVA mean difference was greater for untreated eyes at 24 months (− 0.09 ± 0.15 vs 0.03 ± 0.11 logMAR; p = < 0.001). AREDS2 eyes had decreased cavitary diameter and EZ loss compared to untreated eyes at the study endpoint (p = 0.01 and p = 0.02, respectively). CMT remained stable for both cohorts throughout the study. For better/worse eye analysis, untreated eyes had worse BCVA at 24 months in both better and worse eyes (both p = 0.01). For anatomical outcomes, increases in both EZ loss (p = 0.04) and cavitary diameter (p = 0.001) among untreated eyes were only significant for eyes with worse baseline BCVA.Conclusion: Our results suggest that off-label AREDS2 supplementation in non-proliferative IMT2 may prevent anatomical and visual deterioration in a subset of eyes.Keywords: antioxidant, AREDS2, carotenoid supplementation, ellipsoid zone loss, lutein, idiopathic macular telangiectasia, macular telangiectasia, juxtafoveal macular telangiectasia, parafoveal telangiectasia, retinal vascular diseaseBerger TAManry MWLindsell LBOsher JMMiller DMFoster RERiemann CDPetersen MRSisk RADove Medical Pressarticleantioxidantareds2carotenoid supplementationellipsoid zone lossluteinidiopathic macular telangiectasiamacular telangiectasiajuxtafoveal macular telangiectasiaparafoveal telangiectasiaretinal vascular disease.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 1133-1143 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antioxidant areds2 carotenoid supplementation ellipsoid zone loss lutein idiopathic macular telangiectasia macular telangiectasia juxtafoveal macular telangiectasia parafoveal telangiectasia retinal vascular disease. Ophthalmology RE1-994
spellingShingle	antioxidant areds2 carotenoid supplementation ellipsoid zone loss lutein idiopathic macular telangiectasia macular telangiectasia juxtafoveal macular telangiectasia parafoveal telangiectasia retinal vascular disease. Ophthalmology RE1-994 Berger TA Manry MW Lindsell LB Osher JM Miller DM Foster RE Riemann CD Petersen MR Sisk RA Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia
description	Tyler A Berger,1 Matthew W Manry,1,2 Lucas B Lindsell,1,2 James M Osher,1,2 Daniel M Miller,1,2 Robert E Foster,1,2 Christopher D Riemann,1,2 Michael R Petersen,1,2 Robert A Sisk1– 3 1Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA; 2Cincinnati Eye Institute, Cincinnati, OH, USA; 3Abrahamson Pediatric Eye Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USACorrespondence: Robert A SiskCincinnati Eye Institute, 1945 CEI Drive, Cincinnati, OH, 45242, USAFax +1 513-569-3904Email rsisk@cvphealth.comPurpose: To evaluate if off-label Age-Related Eye Disease Study 2 (AREDS2) supplementation prevents visual and anatomical deterioration in non-proliferative Idiopathic Macular Telangiectasia Type 2 (IMT2).Patients and Methods: This is a single-center retrospective, comparative study of 82 IMT2 eyes treated with AREDS2 from January 1st, 2013 to January 1st, 2018. The study analysis consisted of a non-comparative arm, which included all AREDS2 eyes, and a comparative arm (27 AREDS2 and 42 untreated eyes) that only included eyes with complete follow-up data. Eyes were evaluated at baseline, 12 and 24 months. Better/worse eye sub-analysis was performed in the comparative study arm. Primary outcomes were best corrected visual acuity (BCVA) and optical coherence tomography (OCT) anatomical characteristics including largest cavitation diameter, central macular thickness (CMT), and length of ellipsoid zone (EZ) loss at 24 months.Results: In the non-comparative arm, AREDS2 eyes showed stable BCVA (0.28 ± 0.18 logMAR at baseline vs 0.26 ± 0.19 logMAR at 24 months; p = 0.35) and OCT anatomical features after 24 months of supplementation. In the comparative arm, BCVA mean difference was greater for untreated eyes at 24 months (− 0.09 ± 0.15 vs 0.03 ± 0.11 logMAR; p = < 0.001). AREDS2 eyes had decreased cavitary diameter and EZ loss compared to untreated eyes at the study endpoint (p = 0.01 and p = 0.02, respectively). CMT remained stable for both cohorts throughout the study. For better/worse eye analysis, untreated eyes had worse BCVA at 24 months in both better and worse eyes (both p = 0.01). For anatomical outcomes, increases in both EZ loss (p = 0.04) and cavitary diameter (p = 0.001) among untreated eyes were only significant for eyes with worse baseline BCVA.Conclusion: Our results suggest that off-label AREDS2 supplementation in non-proliferative IMT2 may prevent anatomical and visual deterioration in a subset of eyes.Keywords: antioxidant, AREDS2, carotenoid supplementation, ellipsoid zone loss, lutein, idiopathic macular telangiectasia, macular telangiectasia, juxtafoveal macular telangiectasia, parafoveal telangiectasia, retinal vascular disease
format	article
author	Berger TA Manry MW Lindsell LB Osher JM Miller DM Foster RE Riemann CD Petersen MR Sisk RA
author_facet	Berger TA Manry MW Lindsell LB Osher JM Miller DM Foster RE Riemann CD Petersen MR Sisk RA
author_sort	Berger TA
title	Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia
title_short	Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia
title_full	Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia
title_fullStr	Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia
title_full_unstemmed	Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia
title_sort	outcome of off-label areds 2 supplementation for the treatment of macular degeneration in non-proliferative idiopathic type 2 macular telangiectasia
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/b54a859aabc144b6b64c320b371c802d
work_keys_str_mv	AT bergerta outcomeofofflabelareds2supplementationforthetreatmentofmaculardegenerationinnonproliferativeidiopathictype2maculartelangiectasia AT manrymw outcomeofofflabelareds2supplementationforthetreatmentofmaculardegenerationinnonproliferativeidiopathictype2maculartelangiectasia AT lindselllb outcomeofofflabelareds2supplementationforthetreatmentofmaculardegenerationinnonproliferativeidiopathictype2maculartelangiectasia AT osherjm outcomeofofflabelareds2supplementationforthetreatmentofmaculardegenerationinnonproliferativeidiopathictype2maculartelangiectasia AT millerdm outcomeofofflabelareds2supplementationforthetreatmentofmaculardegenerationinnonproliferativeidiopathictype2maculartelangiectasia AT fosterre outcomeofofflabelareds2supplementationforthetreatmentofmaculardegenerationinnonproliferativeidiopathictype2maculartelangiectasia AT riemanncd outcomeofofflabelareds2supplementationforthetreatmentofmaculardegenerationinnonproliferativeidiopathictype2maculartelangiectasia AT petersenmr outcomeofofflabelareds2supplementationforthetreatmentofmaculardegenerationinnonproliferativeidiopathictype2maculartelangiectasia AT siskra outcomeofofflabelareds2supplementationforthetreatmentofmaculardegenerationinnonproliferativeidiopathictype2maculartelangiectasia
_version_	1718392816136093696

Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia

Ejemplares similares